Back to top
more

IDEXX Laboratories (IDXX)

(Delayed Data from NSDQ)

$472.35 USD

472.35
432,975

+3.17 (0.68%)

Updated Sep 6, 2024 04:00 PM ET

After-Market: $470.94 -1.41 (-0.30%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (70 out of 249)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

LHC Group's (LHCG) Deal With Optum to Boost Value-Based Care

by Zacks Equity Research

LHC Group's (LHCG) deal with Optum is likely to enhance and extend value-based care to patients' homes.

Here's Why You Should Retain Nevro (NVRO) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Nevro (NVRO) owing to its strength in the global SCS market.

Veeva Systems (VEEV) Sees Wider Adoption of Its Development Cloud

by Zacks Equity Research

Adoption of Veeva Systems' (VEEV) cloud applications is likely to significantly boost its Veeva Development Cloud business.

Reasons to Retain Ecolab (ECL) Stock in Your Portfolio For Now

by Zacks Equity Research

Investors continue to be optimistic about Ecolab (ECL) owing to its solid product portfolio.

Henry Schein (HSIC) Digital Dentistry Gains, Expands Globally

by Zacks Equity Research

Henry Schein (HSIC) witnesses strength in dental consumable merchandise sales in France, Germany, Austria, Belgium.

Here's Why You Should Invest in IDEXX (IDXX) Stock for Now

by Zacks Equity Research

Investors are optimistic about IDEXX's (IDXX) strong international performances and favorable 2022 outlook.

Here's Why You Should Retain Globus Medical (GMED) Stock Now

by Zacks Equity Research

Investors are optimistic about Globus Medical's (GMED) better-than-expected results and strength in the U.S. Spine business.

Phibro (PAHC) Rises 6.1% Since Q2 Earnings: What's Driving It?

by Zacks Equity Research

Investors are optimistic about Phibro's (PAHC) booming vaccine business and strong global presence.

National Vision (EYE) Hurt by Rising Costs, Vendor Dependency

by Zacks Equity Research

High dependence on a limited number of suppliers exposes National Vision (EYE) to supplier concentration risk.

Quest Diagnostics' (DGX) Volumes Aid, Price Pressure Stays

by Zacks Equity Research

According to Quest Diagnostics (DGX), the delay of the 2022 PAMA cuts announced last year proved beneficial for the industry and Medicare beneficiaries.

Quest Diagnostics' (DGX) New Contract to Aid COVID-19 Research

by Zacks Equity Research

Quest Diagnostics' (DGX) COVID-19 serological tests, nationwide reach and data analytics capabilities will help assess COVID-19 vulnerability throughout the country.

Should iShares Russell MidCap Growth ETF (IWP) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for IWP

Integra (IART) Debuts NeuraGen 3D for Peripheral Nerve Repair

by Zacks Equity Research

Integra's (IART) NeuraGen 3D will provide surgeons with access to the latest technology in peripheral nerve repair.

Reasons to Add Surmodics (SRDX) Stock to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Surmodics (SRDX) owing to its consistent efforts to boost R&D.

Encompass Health's (EHC) Nationwide Hospital Count Rises to 147

by Zacks Equity Research

Encompass Health (EHC) opens a 60-bed inpatient rehabilitation hospital in Illinois, sustaining its aim to offer enhanced rehabilitation services throughout the United States.

Here's Why You Should Retain Edwards Lifesciences (EW) Now

by Zacks Equity Research

Investors are optimistic about Edwards Lifesciences' (EW) robust segmental performance and growing product uptake.

Reasons to Add Allscripts (MDRX) Stock to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Allscripts Healthcare Solutions (MDRX) owing to its strategic alliances.

Here's Why You Should Hold on to Alcon (ALC) Stock for Now

by Zacks Equity Research

Investors are optimistic about Alcon's (ALC) better-than-expected results and robust segmental performance.

Reasons to Add AMN Healthcare (AMN) Stock to Your Portfolio

by Zacks Equity Research

Investors remain optimistic about AMN Healthcare (AMN) on its broad array of services.

Is it the Right Time to Add Mednax (MD) Stock to Your Kitty?

by Zacks Equity Research

Growing revenues, numerous acquisitions, diversified care network and adequate cash generation abilities are likely to continue driving Mednax (MD).

Molina Healthcare (MOH) Up 32% in a Year: Is More Upside Left?

by Zacks Equity Research

Continued revenue growth, well-performing Medicaid and Medicare businesses, expense saving initiatives and solid cash balance continue to drive Molina Healthcare (MOH).

Should iShares Russell MidCap ETF (IWR) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for IWR

Idexx (IDXX) Down 0.1% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Mark Vickery headshot

Top Analyst Reports for salesforce, General Motors & Block

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including salesforce.com, inc. (CRM), General Motors Company (GM), and Block, Inc. (SQ).

Here's Why You Should Hold on to IDEXX (IDXX) Stock for Now

by Zacks Equity Research

Robust domestic and international performances by the CAG arm are driving IDEXX's (IDXX) fourth-quarter top line.